Kaitlyn D’Onofrio

DocwireNews

Baricitinib, a rheumatoid arthritis treatment drug manufactured by Eli Lilly, will be tested in a trial of patients who are seriously ill with <a href="https://www.docwirenews.com/home-page-editor-picks/the-covid-19-pandemic-us-nears-peak-death-rate-as-curve-may-be-flattening-boris-johnson-out-of-intensive-care-and-more/">COVID-19.</a>Eli Lilly is teaming up with the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, to kick off this arm of the Adaptive COVID-19 Treatment Trial in the U.S. this month, with plans to eventually expand to other countries in Europe and Asia. The phase 2/3 trial will take place at the University of Colorado.Lilly also announced the advancement of LY3127804, an investigational selective monoclonal antibody against Angiopoietin 2 (Ang2), to phase 2 testing in hospitalized COVID-19 patients with pneumonia at serious risk of developing acute respiratory distress syndrome.&ldquo;Lilly&nbsp;is moving at top speed and using all available resources to help fight this pandemic,&rdquo; said&nbsp;Daniel Skovronsky, MD, PhD,&nbsp;Lilly&rsquo;s chief scientific officer and president of&nbsp;Lilly Research Laboratories, <a href="https://investor.lilly.com/news-releases/news-release-details/lilly-begins-clinical-testing-therapies-covid-19">in a press release</a>. &ldquo;Developing potential therapeutic medicines for COVID-19 is part of our vital and humanitarian mission. To be successful, we must combine resources, data and expertise, with government, academia and other companies. We look forward to seeing the results of baricitinib and anti-Ang2 clinical studies.&rdquo;Baricitinib, marketed as OLUMIANT, comes with a boxed warning that it carries a risk for serious infections, possibly because the drug affects the body&rsquo;s immune system, according to Lilly. The warning states, &ldquo;Patients treated with Olumiant are at risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. If a serious infection develops, interrupt Olumiant until the infection is controlled.&rdquo;The most commonly reported serious infections associated with the drug are pneumonia, herpes zoster, and urinary tract infection.However, the company said in a press release, &ldquo;Given the inflammatory cascade seen in COVID-19, baricitinib&rsquo;s anti-inflammatory activity has been hypothesized to have a potential beneficial effect in COVID-19 and warrants further study in patients with this infection.&rdquo;Correspondence published in <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30304-4/fulltext?rss=yes#articleInformation&amp;mod=article_inline">The Lancet</a> earlier this year theorized that baricitinib may effectively treat COVID-19, saying the drug is &ldquo;predicted to reduce the ability of the virus to infect lung cells.&rdquo;Lilly said that it does not anticipate <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/amid-covid-19-outbreak-pharmacies-are-limiting-hydroxychloroquine-prescriptions-leaving-lupus-and-ra-patients-without-medication/">shortages of the drug</a> will occur and said it is prepared to &ldquo;create adequate supply to support both appropriate clinical and investigational use.&rdquo;

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Despite Infection Warning, Arthritis Drug Baricitinib Will Be Tested in Seriously Ill COVID-19 Patients

COVID-19

Baricitinib, a rheumatoid arthritis treatment drug manufactured by Eli Lilly, will be tested in a trial of patients who are seriously ill with COVID-19. ...

Despite Infection Warning, Arthritis Drug Baricitinib Will Be Tested in Seriously Ill COVID-19

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe